CD81 通过阻断 CD274/PD-L1 的选择性自噬降解驱动放射抵抗性胶质母细胞瘤的免疫逃逸
CD81 drives immune evasion in radioresistant glioblastoma by blocking selective autophagic degradation of CD274/PD-L1.
肿瘤细胞治疗研究
英文原题:Innovations in peptide-based targeted therapies for breast cancer: From conjugates to precision delivery.
Innovations in peptide-based targeted therapies for breast cancer: From conjugates to precision delivery.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
乳腺癌仍是全球女性死亡的主要原因之一,因此需要将精准靶向与有效递送相结合的治疗创新。肽已成为乳腺癌靶向治疗中的多功能工具,在多种平台中作为肿瘤靶向配体、疫苗表位和递送增强剂发挥作用,这些平台包括外泌体、纳米颗粒、药物偶联物和工程化免疫细胞。这些多功能系统利用肽固有的特异性和适应性,实现精准药物递送、干扰致癌信号通路、调节肿瘤微环境并克服治疗耐药性,从而解决传统乳腺癌治疗的局限性。本综述介绍了基于肽的靶向治疗的最新进展,强调仍需应对肿瘤异质性和耐药性。
Breast cancer remains a leading cause of mortality among women worldwide, necessitating therapeutic innovations that combine precision targeting with effective delivery. Peptides have emerged as versatile tools in breast cancer-targeted therapy, functioning as tumor-targeting ligands, vaccine epitopes, and delivery enhancers across various platforms, including exosomes, nanoparticles, drug conjugates, and engineered immune cells.
These multifunctional systems address limitations of conventional breast cancer therapies by leveraging the inherent specificity and adaptability of peptides to enable precise drug delivery, disrupt oncogenic signaling pathways, modulate the tumor microenvironment, and overcome therapeutic resistance. This review presents recent advances in peptide-based targeted therapies, highlighting the ongoing need to address tumor heterogeneity and resistance.
MEMBER ACCOUNT
登录成功会直接打开下一页。